Search

Your search keyword '"Guidoboni M"' showing total 196 results
Start Over Author "Guidoboni M"
196 results on '"Guidoboni M"'

1. 51P Phase IB (Ph1b), MESOVAX clinical trial of pembrolizumab (P) and dendritic cell vaccine (DCvax) in advanced pleural and peritoneal mesothelioma (M): Preliminary results

Author

Ridolfi, L., primary, Delmonte, A., additional, De Rosa, F., additional, Azzali, I., additional, Gentili, G., additional, Petrini, M., additional, Pancisi, E., additional, Granato, A.M., additional, Bulgarelli, J., additional, Doglioni, C., additional, Burgio, M.A., additional, Ragonesi, M., additional, Stella, F., additional, Cortesi, P., additional, Casadei, C., additional, Garaffoni, M., additional, Barone, D., additional, and Guidoboni, M., additional

Published
2023
Full Text
View/download PDF

2. Italian Nivolumab Expanded Access Program (EAP) in Melanoma Adjuvant Setting: patient outcomes and safety profil

Author

Ascierto, P.A., primary, Di Giacomo, A.M., additional, Chiarion Sileni, V., additional, Queirolo, P., additional, Spagnolo, F., additional, De Galitiis, F., additional, Cognetti, F., additional, Mandalà, M., additional, Guidoboni, M., additional, Rinaldi, G., additional, Depenni, R., additional, Consoli, F., additional, Troiani, T., additional, Guida, M., additional, Marconcini, R., additional, Ferrucci, P.F., additional, Strippoli, S., additional, Fava, P., additional, Merelli, B., additional, Simeone, E., additional, Di Guardo, L., additional, Giannarelli, D., additional, Maio, M., additional, Quaglino, P., additional, and Del Vecchio, M., additional

Published
2023
Full Text
View/download PDF

3. Neoadjuvant plus adjuvant combined or sequenced vemurafenib, cobimetinib and atezolizumab in patients with high-risk, resectable BRAF-mutated and wild-type melanoma: NEO-TIM, a phase II randomized non-comparative study

Author

Ascierto, P. A., Cioli, E., Chiarion-Sileni, V., Quaglino, P., Spagnolo, F., Guidoboni, M., Del Vecchio, M., Peris, Ketty, Queirolo, P., Fioretto, L., Caraco, C., Paone, M., Sorrentino, A., Capone, M., Giannarelli, Diana, Ferrara, G., Massi, D., Trojaniello, C., Peris K. (ORCID:0000-0002-5237-0463), Giannarelli D., Ascierto, P. A., Cioli, E., Chiarion-Sileni, V., Quaglino, P., Spagnolo, F., Guidoboni, M., Del Vecchio, M., Peris, Ketty, Queirolo, P., Fioretto, L., Caraco, C., Paone, M., Sorrentino, A., Capone, M., Giannarelli, Diana, Ferrara, G., Massi, D., Trojaniello, C., Peris K. (ORCID:0000-0002-5237-0463), and Giannarelli D.

Abstract

Background: Following the increased survival of patients with metastatic melanoma thanks to immunotherapy and targeted therapy, neoadjuvant approaches are being investigated to address the unmet needs of unresponsive and intolerant patients. We aim to investigate the efficacy of neoadjuvant plus adjuvant combined or sequenced vemurafenib, cobimetinib and atezolizumab in patients with high-risk, resectable BRAF-mutated and wild-type melanoma. Methods: The study is a phase II, open-label, randomized non-comparative trial in patients with stage IIIB/C/D surgically resectable, BRAF-mutated and wild-type melanoma, with three possible treatments: (1) vemurafenib 960 mg twice daily from day 1 to 42; (2) vemurafenib 720 mg twice daily from day 1 to 42; (3) cobimetinib 60 mg once daily from day 1 to 21 and from day 29 to 42; and (4) atezolizumab 840 mg for two cycles (day 22 and day 43). Patients will be randomized to three different arms: A) BRAF-mutated patients will receive over 6 weeks (1) + (3); B) BRAF-mutated patients will receive over 6 weeks (2) + (3) + (4); C) BRAF wild-type patients will receive over 6 weeks (3) + (4). All patients will also receive atezolizumab 1200 mg every 3 weeks for 17 cycles after surgery and after a second screening period (up to 6 weeks). Discussion: Neoadjuvant therapy for regional metastases may improve operability and outcomes and facilitate the identification of biomarkers that can guide further lines of treatment. Patients with clinical stage III melanoma may especially benefit from neoadjuvant treatment, as the outcomes of surgery alone are very poor. It is expected that the combination of neoadjuvant and adjuvant treatment may reduce the incidence of relapse and improve survival. Clinical trial registration: eudract.ema.europa.eu/protocol.htm, identifier 2018-004841-17.

Published
2023

6. LBA41 Phase II study SECOMBIT (sequential combo immuno and target therapy study): 4-years OS data and preliminary biomarkers evaluation

Author

Ascierto, P.A., primary, Mandala, M., additional, Ferrucci, P.F., additional, Guidoboni, M., additional, Rutkowski, P., additional, Ferraresi, V., additional, Fernandez, A.M. Arance, additional, Guida, M., additional, Maiello, E., additional, Gogas, H.J., additional, Richtig, E., additional, Fierro, M.T., additional, Lebbe, C., additional, Helgadottir, H., additional, Melero, I., additional, Palmieri, G., additional, Giannarelli, D., additional, Grimaldi, A.M., additional, Dummer, R., additional, and Sileni, V. Chiarion, additional

Published
2022
Full Text
View/download PDF

8. 48P Phase II trial on vaccination with autologous dendritic cells loaded with autologous tumour homogenate in resected glioblastoma (COMBI-GVAX): Clinical results of the first step

Author

Ridolfi, L., Gurrieri, L., Riva, M.N., Bulgarelli, J., Fausti, V., F. de Rosa, Guidoboni, M., Foca, F., Tazzari, M., Petrini, M., Granato, A.M., Pancisi, E., Dall'Agata, M., Amadori, E., Gamboni, A., Pasini, G., Cortesi, P., Mercatali, L., Bongiovanni, A., and Tosatto, L.

Published
2022
Full Text
View/download PDF

9. The surgical treatment of non-metastatic melanoma in a Clinical National Melanoma Registry Study Group (CNMR): a retrospective cohort quality improvement study to reduce the morbidity rates

Author

Vecchiato, A., Mocellin, S., Del Fiore, P., Tosti, G., Ascierto, P. A., Corradin, M. T., De Giorgi, V., Giudice, G., Queirolo, P., Ferreli, C., Occelli, M., Giordano, M., Trevisan, G., Mascheroni, L., Testori, A., Spina, R., Buja, A., Cavallin, F., Caraco, C., Sommariva, A., Rossi, C. R., Asero, S., Barbati, R., Bianchi, L., Bruder, F., Catricala, C., Cinieri, S., Del Vecchio, M., Di Filippo, F., Fargnoli, M. C., Fierro, M. T., Forcignano, R., Guidoboni, M., Iacono, C., Lospalluti, L., Maio, M., Milesi, L., Moise, G., Moretti, G., Pellicano, R., Pizzichetta, M. A., Rinaldi, G., Sanna, G., Staibano, S., Visini, M., Zannetti, G., Zichichi, L., Vecchiato, A., Mocellin, S., Del Fiore, P., Tosti, G., Ascierto, P. A., Corradin, M. T., De Giorgi, V., Giudice, G., Queirolo, P., Ferreli, C., Occelli, M., Giordano, M., Trevisan, G., Mascheroni, L., Testori, A., Spina, R., Buja, A., Cavallin, F., Caraco, C., Sommariva, A., Rossi, C. R., Asero, S., Barbati, R., Bianchi, L., Bruder, F., Catricala, C., Cinieri, S., Del Vecchio, M., Di Filippo, F., Fargnoli, M. C., Fierro, M. T., Forcignano, R., Guidoboni, M., Iacono, C., Lospalluti, L., Maio, M., Milesi, L., Moise, G., Moretti, G., Pellicano, R., Pizzichetta, M. A., Rinaldi, G., Sanna, G., Staibano, S., Visini, M., Zannetti, G., Zichichi, L., Clinical National Melanoma Registry Study Group at the Italian Melanoma Intergroup (IMI): Salvatore Asero, Vecchiato A., Mocellin S., Del Fiore P., Tosti G., Ascierto P. A., Corradin M. T., De Giorgi V., Giudice G., Queirolo P., Ferreli C., Occelli M., Giordano M., Trevisan G., Mascheroni L., Testori A., Spina R., Buja A., Cavallin F., Caraco C., Sommariva A., Rossi C. R., Asero S., Barbati R., Bianchi L., Bruder F., Catricala C., Cinieri S., Del Vecchio M., Di Filippo F., Fargnoli M. C., Fierro M. T., Forcignano R., Guidoboni M., Iacono C., Lospalluti L., Maio M., Milesi L., Moise G., Moretti G., Pellicano R., Pizzichetta M. A., Rinaldi G., Sanna G., Staibano S., Visini M., Zannetti G., Zichichi L., Barbati, Rosanna, Bianchi, Luca, Bruder, Francesca, Catricalà, Caterina, Cinieri, Saverio, Del Vecchio, Michele, Di Filippo, Franco, Concetta Fargnoli, Maria, Teresa Fierro, Maria, Forcignanò, Rosachiara, Guidoboni, Massimo, Iacono, Carmelo, Lospalluti, Lucia, Maio, Michele, Milesi, Laura, Moise, Gianmichele, Moretti, Giovanna, Pellicano, Riccardo, Antonietta Pizzichetta, Maria, Rinaldi, Gaetana, Sanna, Giovanni, Staibano, Stefania, Visini, Marilena, Zannetti, Guido, and Zichichi), Leonardo

Subjects
Registrie, Male, Cancer Research, Skin Neoplasms, 0302 clinical medicine, Surgical oncology, Retrospective Studie, Melanoma quality improvement, 030212 general & internal medicine, Prospective Studies, Registries, Melanoma, Melanoma surgical treatment, Middle Aged, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Prognosis, Quality Improvement, Survival Rate, Oncology, Italy, 030220 oncology & carcinogenesis, Melanoma morbidity, Skin Cancer, Female, Human, Research Article, medicine.medical_specialty, Prognosi, Dehiscence, lcsh:RC254-282, Follow-Up Studie, 03 medical and health sciences, Settore MED/35, Internal medicine, Genetics, medicine, Humans, Skin Neoplasm, Aged, Retrospective Studies, business.industry, Wound dehiscence, Sentinel Lymph Node Biopsy, Cancer, Retrospective cohort study, medicine.disease, Prospective Studie, Seroma, Lymph Node Excision, Skin cancer, Morbidity, business, Follow-Up Studies
Abstract

Background Reproducible, high-quality surgery is a key point in the management of cancer patients. Quality indicators for surgical treatment of melanoma has been presented with benchmarks but data on morbidity are still limited. This study presents the quality indicators on morbidity after surgical treatment for non-metastatic skin melanoma in an Italian registry. Methods Data were extracted from the Central National Melanoma Registry (CNMR) promoted by the Italian Melanoma Intergroup (IMI). All surgical procedures (WE, SNLB or LFND) for non-metastatic skin melanoma between January 2011 and February 2017 were evaluated for inclusion in the study. Only centers with adequate completeness of information (> 80%) were included in the study. Short-term complications (wound infection, dehiscence, skin graft failure and seroma) were investigated. Results Wound infection rate was 1.1% (0.4 to 2.7%) in WE, 1.3% (0.7 to 2.5%) in SLNB and 4.1% (2.1 to 8.0%) in LFND. Wound dehiscence rate was 2.0% (0.8 to 5.1%) in WE, 0.9% (0.2 to 3.0%) in SLNB and 2.8% (0.9 to 8.6%) in LFND. Seroma rate was 4.2% (1.5 to 11.1%) in SLNB and 15.1% (4.6 to 39.9%) in LFND. Unreliable information was found on skin graft failure. Conclusions Our findings contribute to available literature in setting up the recommended standards for melanoma centers, thus improving the quality of surgery offered to patients. A consensus on the core issues around surgical morbidity is needed to provide practical guidance on morbidity prevention and management.

Published
2020

10. Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma

Author

Wolchok, JD, Chiarion-Sileni, V, Gonzalez, R, Grob, J-J, Rutkowski, P, Lao, CD, Cowey, CL, Schadendorf, D, Wagstaff, J, Dummer, R, Ferrucci, PF, Smylie, M, Butler, MO, Hill, A, Marquez-Rodas, I, Haanen, JBAG, Guidoboni, M, Maio, M, Schoffski, P, Carlino, MS, Lebbe, C, McArthur, G, Ascierto, PA, Daniels, GA, Long, G, Bas, T, Ritchings, C, Larkin, J, Hodi, FS, Wolchok, JD, Chiarion-Sileni, V, Gonzalez, R, Grob, J-J, Rutkowski, P, Lao, CD, Cowey, CL, Schadendorf, D, Wagstaff, J, Dummer, R, Ferrucci, PF, Smylie, M, Butler, MO, Hill, A, Marquez-Rodas, I, Haanen, JBAG, Guidoboni, M, Maio, M, Schoffski, P, Carlino, MS, Lebbe, C, McArthur, G, Ascierto, PA, Daniels, GA, Long, G, Bas, T, Ritchings, C, Larkin, J, and Hodi, FS

Abstract

PURPOSE: In the phase III CheckMate 067 trial, durable clinical benefit was demonstrated previously with nivolumab plus ipilimumab and nivolumab alone versus ipilimumab. Here, we report 6.5-year efficacy and safety outcomes. PATIENTS AND METHODS: Patients with previously untreated unresectable stage III or stage IV melanoma were randomly assigned 1:1:1 to receive nivolumab 1 mg/kg plus ipilimumab 3 mg/kg once every 3 weeks (four doses) followed by nivolumab 3 mg/kg once every 2 weeks (n = 314), nivolumab 3 mg/kg once every 2 weeks (n = 316), or ipilimumab 3 mg/kg once every 3 weeks (four doses; n = 315). Coprimary end points were progression-free survival and overall survival (OS) with nivolumab plus ipilimumab or nivolumab versus ipilimumab. Secondary end points included objective response rate, descriptive efficacy assessments of nivolumab plus ipilimumab versus nivolumab alone, and safety. Melanoma-specific survival (MSS; descriptive analysis), which excludes deaths unrelated to melanoma, was also evaluated. RESULTS: Median OS (minimum follow-up, 6.5 years) was 72.1, 36.9, and 19.9 months in the combination, nivolumab, and ipilimumab groups, respectively. Median MSS was not reached, 58.7, and 21.9 months, respectively; 6.5-year OS rates were 57%, 43%, and 25% in patients with BRAF-mutant tumors and 46%, 42%, and 22% in those with BRAF-wild-type tumors, respectively. In patients who discontinued treatment, the median treatment-free interval was 27.6, 2.3, and 1.9 months, respectively. Since the 5-year analysis, no new safety signals were observed. CONCLUSION: These 6.5-year CheckMate 067 results, which include the longest median OS in a phase III melanoma trial reported to date and the first report of MSS, showed durable, improved clinical outcomes with nivolumab plus ipilimumab or nivolumab versus ipilimumab in patients with advanced melanoma and, in descriptive analyses, with the combination over nivolumab monotherapy.

Published
2022

11. 49P A phase II randomized trial with adjuvant autologous tumor lysate-pulsed dendritic cells (DC) in resected stage III-IV melanoma patients: Preliminary immunological results

Author

Ridolfi, L., primary, Bulgarelli, J., additional, Piccinini, C., additional, Carloni, S., additional, Granato, A., additional, Petrini, M., additional, De Rosa, F., additional, Tazzari, M., additional, Pancisi, E., additional, Ancarani, V., additional, Turci, L., additional, Gentili, G., additional, Valmorri, L., additional, and Guidoboni, M., additional

Published
2021
Full Text
View/download PDF

12. Dendritic Cell Vaccination in Metastatic Melanoma Turns “Non-T Cell Inflamed” Into “T-Cell Inflamed” Tumors

Author

Bulgarelli, J, Tazzari, M, Granato, A, Ridolfi, L, Maiocchi, S, de Rosa, F, Petrini, M, Pancisi, E, Gentili, G, Vergani, B, Piccinini, F, Carbonaro, A, Leone, B, Foschi, G, Ancarani, V, Framarini, M, Guidoboni, M, Bulgarelli J, Tazzari M, Granato AM, Ridolfi L, Maiocchi S, de Rosa F, Petrini M, Pancisi E, Gentili G, Vergani B, Piccinini F, Carbonaro A, Leone BE, Foschi G, Ancarani V, Framarini M, Guidoboni M., Bulgarelli, J, Tazzari, M, Granato, A, Ridolfi, L, Maiocchi, S, de Rosa, F, Petrini, M, Pancisi, E, Gentili, G, Vergani, B, Piccinini, F, Carbonaro, A, Leone, B, Foschi, G, Ancarani, V, Framarini, M, Guidoboni, M, Bulgarelli J, Tazzari M, Granato AM, Ridolfi L, Maiocchi S, de Rosa F, Petrini M, Pancisi E, Gentili G, Vergani B, Piccinini F, Carbonaro A, Leone BE, Foschi G, Ancarani V, Framarini M, and Guidoboni M.

Abstract

Dendritic cell (DC)-based vaccination effectively induces anti-tumor immunity, although in the majority of cases this does not translate into a durable clinical response. However, DC vaccination is characterized by a robust safety profile, making this treatment a potential candidate for effective combination cancer immunotherapy. To explore this possibility, understanding changes occurring in the tumor microenvironment (TME) upon DC vaccination is required. In this line, quantitative and qualitative changes in tumor-infiltrating T lymphocytes (TILs) induced by vaccination with autologous tumor lysate/homogenate loaded DCs were investigated in a series of 16 patients with metastatic melanoma. Immunohistochemistry for CD4, CD8, Foxp3, Granzyme B (GZMB), PDL1, and HLA class I was performed in tumor biopsies collected before and after DC vaccination. The density of each marker was quantified by automated digital pathology analysis on whole slide images. Co-expression of markers defining functional phenotypes, i.e., Foxp3+ regulatory CD4+ T cells (Treg) and GZMB+ cytotoxic CD8+ T cells, was assessed with sequential immunohistochemistry. A significant increase of CD8+ TILs was found in post-vaccine biopsies of patients who were not previously treated with immune-modulating cytokines or Ipilimumab. Interestingly, along with a maintained tumoral HLA class I expression, after DC vaccination we observed a significant increase of PDL1+ tumor cells, which significantly correlated with intratumoral CD8+ T cell density. This observation might explain the lack of a significant concurrent cytotoxic reactivation of CD8+ T cell, as measured by the numbers of GZMB+ T cells. Altogether these findings indicate that DC vaccination exerts an important role in sustaining or de novo inducing a T cell inflamed TME. However, the strength of the intratumoral T cell activation detected in post-DC therapy lesions is lessened by an occurring phenomenon of adaptive immune resistance, yet the conco

Published
2019

13. 381TiP Vaccination with autologous dendritic cells loaded with autologous tumour homogenate in resected glioblastoma: A phase II study (CombiGVax)

Author

Ridolfi, L., primary, Gurrieri, L., additional, Riva, N., additional, Fausti, V., additional, Bongiovanni, A., additional, Di Menna, G., additional, de Rosa, F., additional, Guidoboni, M., additional, Mercatali, L., additional, Bulgarelli, J., additional, Foca, F., additional, Tazzari, M., additional, Calpona, S., additional, Petrini, M., additional, Granato, A., additional, Pancisi, E., additional, Dall'Agata, M., additional, Valmorri, L., additional, Tosatto, L., additional, and Ibrahim, T., additional

Published
2021
Full Text
View/download PDF

14. LBA40 SECOMBIT: The best sequential approach with combo immunotherapy [ipilimumab (I) /nivolumab (N)] and combo target therapy [encorafenib (E)/binimetinib (B)] in patients with BRAF mutated metastatic melanoma: A phase II randomized study

Author

Ascierto, P.A., primary, Mandala, M., additional, Ferrucci, P.F., additional, Rutkowski, P., additional, Guidoboni, M., additional, Arance Fernandez, A.M., additional, Ferraresi, V., additional, Maiello, E., additional, Guida, M., additional, Del Vecchio, M., additional, Fierro, M.T., additional, Queirolo, P., additional, Lebbe, C., additional, Helgadottir, H., additional, Melero, I., additional, Palmieri, G., additional, Giannarelli, D., additional, Grimaldi, A.M., additional, Dummer, R., additional, and Chiarion Sileni, V., additional

Published
2021
Full Text
View/download PDF

15. Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study

Author

Di Giacomo, A. M., Ascierto, P. A., Queirolo, P., Pilla, L., Ridolfi, R., Santinami, M., Testori, A., Simeone, E., Guidoboni, M., Maurichi, A., Orgiano, L., Spadola, G., Del Vecchio, M., Danielli, R., Calabrò, L., Annesi, D., Giannarelli, D., Maccalli, C., Fonsatti, E., Parmiani, G., and Maio, M.

Published
2015
Full Text
View/download PDF

18. Dendritic cell vaccines manufacturing for treatment of cancer patients: a 11-year product quality control test collection of an advanced therapy medicinal product and compliance with the good manufacturing practices guideline

Author

Granato, A., primary, Petrini, M., additional, Pancisi, E., additional, Piccinini, C., additional, Soldati, V., additional, Carloni, S., additional, Bulgarelli, J., additional, Tazzari, M., additional, Ridolfi, L., additional, De rosa, F., additional, Guidoboni, M., additional, and Ibrahim, T., additional

Published
2021
Full Text
View/download PDF

19. Efficacy of ipilimumab plus nivolumab or ipilimumab plus fotemustine vs fotemustine in patients with melanoma metastatic to the brain: Primary analysis of the phase III NIBIT-M2 trial

Author

Di Giacomo, A. M., Chiarion Sileni, V., Del Vecchio, M., Ferrucci, P. F., Guida, M., Quaglino, P., Guidoboni, M., Marchetti, P., Cutaia, O., Amato, G., Gambale, E., Calabrò, L., Valente, M., Danielli, R., Giannarelli, D., Mandala, M., and Maio, M.

Subjects
nivolumab, brain metastases, brain metastases, ipilimumab, nivolumab, fotemustine, ipilimumab, fotemustine
Published
2020

22. 1081MO Efficacy of ipilimumab plus nivolumab or ipilimumab plus fotemustine vs fotemustine in patients with melanoma metastatic to the brain: Primary analysis of the phase III NIBIT-M2 trial

Author

Di Giacomo, A.M., primary, Sileni, V. Chiarion, additional, Del Vecchio, M., additional, Ferrucci, P.F., additional, Guida, M., additional, Quaglino, P., additional, Guidoboni, M., additional, Marchetti, P., additional, Cutaia, O., additional, Amato, G., additional, Gambale, E., additional, Calabrò, L., additional, Valente, M., additional, Danielli, R., additional, Giannarelli, D., additional, Mandala, M., additional, and Maio, M., additional

Published
2020
Full Text
View/download PDF

23. LBA45 First report of efficacy and safety from the phase II study SECOMBIT (SEquential COMBo Immuno and Targeted therapy study)

Author

Ascierto, P.A., primary, Mandala, M., additional, Ferrucci, P.F., additional, Rutkowski, P., additional, Guidoboni, M., additional, Fernandez, A.M. Arance, additional, Ferraresi, V., additional, Maiello, E., additional, Guida, M., additional, Del Vecchio, M., additional, Fierro, M.T., additional, Queirolo, P., additional, Lebbé, C., additional, Helgadottir, H., additional, Melero, I., additional, Palmieri, G., additional, Giannarelli, D., additional, Grimaldi, A.M., additional, Dummer, R., additional, and Chiarion Sileni, V., additional

Published
2020
Full Text
View/download PDF

24. Radiotherapy as an Immunological Booster in Patients with Metastatic Melanoma or Renal Cell Carcinoma Treated with High-Dose Interleukin-2: Final Data

Author

Ridolfi, L., primary, Bulgarelli, J., additional, Petracci, E., additional, Pancisi, E., additional, Piccinini, C., additional, Granato, A., additional, Petrini, M., additional, Tazzari, M., additional, Ancarani, V., additional, Turci, L., additional, Gentili, G., additional, Valmorri, L., additional, Romeo, A., additional, De Giorgi, U.F.F., additional, Burgio, S.L., additional, Casadei, C., additional, Cortesi, P., additional, Lolli, C., additional, De Rosa, F., additional, and Guidoboni, M., additional

Published
2019
Full Text
View/download PDF

27. Corrigendum: Association of CTLA-4 gene variants with response to therapy and long-term survival in metastatic melanoma patients treated with ipilimumab: An Italian melanoma intergroup study [Front Immunol, 8, (2017), (386)] doi: 10.3389/fimmu.2017.00386

Author

Queirolo, P., Dozin, B., Morabito, A., Banelli, B., Piccioli, P., Fava, C., Leo, C., Carosio, R., Laurent, S., Fontana, V., Ferrucci, P. F., Martinoli, C., Cocorocchio, E., Battaglia, A., Ascierto, P. A., Capone, M., Simeone, E., De Galitiis, F., Pagani, E., Cappellini, G. C. A., Marchetti, P., Guida, M., Tommasi, S., Mandala, M., Merelli, B., Quaglino, P., Fava, P., Guidoboni, M., Romani, M., Spagnolo, F., and Pistillo, M. P.

Subjects
Best overall response, CTLA-4 variants, Ipilimumab, Melanoma, Overall survival, Predictive/prognostic factor
Published
2018

28. ILLUMINATE 301: A randomized phase III study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy

Author

Butler, M.O., primary, Robert, C., additional, Negrier, S., additional, In, G.K., additional, Walker, J., additional, Krajsova, I., additional, Atkinson, V.G., additional, Hansson, J., additional, Kapiteijn, E., additional, Loquai, C., additional, Shaw, H.M., additional, Cheng, T., additional, Mansard, S., additional, Grob, J.J., additional, Guidoboni, M., additional, Mehta, M., additional, Ascierto, P.A., additional, and Diab, A., additional

Published
2019
Full Text
View/download PDF

31. 1373TiP - ILLUMINATE 301: A randomized phase III study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy

Author

Butler, M.O., Robert, C., Negrier, S., In, G.K., Walker, J., Krajsova, I., Atkinson, V.G., Hansson, J., Kapiteijn, E., Loquai, C., Shaw, H.M., Cheng, T., Mansard, S., Grob, J.J., Guidoboni, M., Mehta, M., Ascierto, P.A., and Diab, A.

Published
2019
Full Text
View/download PDF

34. Safety profile of nivolumab (NIVO) and ipilimumab (IPI) combination therapy in patients (pts) with advanced melanoma (MEL)

Author

Sznol, M., primary, Ferrucci, P.F., additional, Hogg, D., additional, Atkins, M., additional, Wolter, P., additional, Guidoboni, M., additional, Lebbe, C., additional, Kirkwood, J., additional, Schachter, J., additional, Daniels, G., additional, Hassel, J., additional, Cebon, J., additional, Gerritsen, W., additional, Atkinson, V., additional, Thomas, L., additional, McCaffrey, J., additional, Power, D., additional, Jiang, J., additional, Hodi, F.S., additional, and Wolchok, J., additional

Published
2016
Full Text
View/download PDF

35. Rituximab in patients with mucosal-associated lymphold tissue-type lymphoma of the ocular adnexa

Author

Ferreri AJM, Martinelli G, Muti G, Guidoboni M, Dolcetti R, Doglioni C., PONZONI , MAURILIO, Ferreri, Ajm, Ponzoni, Maurilio, Martinelli, G, Muti, G, Guidoboni, M, Dolcetti, R, and Doglioni, C.

Abstract

Eight patients with ocular adnexal mucosal-associated lymphpid tissue (MALT) lymphoma. were treated with rituximab, at diagnosis (n=5) or relapse (n=3). All untreated patients achieved lymphoma regression, while relapsing patients had no benefit. Four responding patients experienced early relapse. The median time to progression was 5 months. The efficacy of rituximab in ocular adnexal lymphoma is lower than that reported for gastric MALT lymphomas.

Published
2005

38. THE HIGH PREVALENCE OF CHLAMYDIA PSITTACI INFECTION IN OCULAR ADNEXAL LYMPHOMAS (OAL) PROVIDES THE RATIONALE FOR THE USE OF ANTIBIOTICS AS A POTENTIAL THERAPEUTIC STRATEGY IN THESE PATIENTS

Author

Ferreri AJM, Guidoboni M, De Conciliis C, Resti AG, Dell'Oro S, Mazzi B, Caggiari L, Lettini AA, Freschi M, Villa E, Boiocchi M, Dolcetti R., PONZONI , MAURILIO, DOGLIONI , CLAUDIO, Ferreri, Ajm, Guidoboni, M, Ponzoni, Maurilio, De Conciliis, C, Resti, Ag, Dell'Oro, S, Mazzi, B, Caggiari, L, Lettini, Aa, Freschi, M, Doglioni, Claudio, Villa, E, Boiocchi, M, and Dolcetti, R.

Published
2004

39. Tenth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), SIENA, Italy, November 5-7, 2012

Author

Maio, M., Nicolay, H. J. M., Ascierto, P. A., Belardelli, F., Camerini, R., Colombo, M. P., Queirolo, P., Ridolfi, R., Russo, V., Parisi, G., Cutaia, O., Fonsatti, E., Parmiani, G., Mennonna, D., Carluccio, S., Bellone, M., Maccalli, C., Brendolan, A., Mondino, A., Corti, A., Bondanza, A., Locatelli, F., Seliger, B., Filaci, G., Rosato, A., Pittoni, P., Tazzari, M., Rivoltini, L., Anichini, A., Vallacchi, V., Zappasodi, R., Quaglino, E., Moresco, R. M., Camisaschi, C., Calabro, L., Ferrucci, P. F., Fratta, E., Ugel, S., van Baren, N., Guidoboni, M., Covre, A., Carbone, E., Aurisicchio, L., Palmieri, G., Di Giacomo, A. M., Volonte, A., Jachetti, E., and Sangiolo, D.

Subjects
Cancer Research, medicine.medical_specialty, business.industry, Immunology, Cancer, medicine.disease, NIBIT, Oncology, Family medicine, Immunotherapy, Networks, Cancer, Immunology, Immunotherapy, Networks, NIBIT, Immunology and Allergy, Medicine, business
Published
2013

41. Isolated bone marrow manifestation of HIV-related Hodgkin Lymphoma

Author

PONZONI , MAURILIO, Fumagalli L, Rossi G, Freschi M, Re A, Vigano MG, Guidoboni M, Dolcetti R, McKenna RW, Facchetti F., Ponzoni, Maurilio, Fumagalli, L, Rossi, G, Freschi, M, Re, A, Vigano, Mg, Guidoboni, M, Dolcetti, R, Mckenna, Rw, and Facchetti, F.

Published
2001

46. Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian ipilimumab expanded access programme (EAP)

Author

Ascierto, Paolo Antonio, primary, Simeone, E, additional, Sileni, V Chiarion, additional, Queirolo, P, additional, Del Vecchio, M, additional, Di Guardo, L, additional, Guidoboni, M, additional, Marchetti, P, additional, Cappellini, GC Antonini, additional, Ferrucci, PF, additional, Cognetti, F, additional, Bernengo, MG, additional, Guida, M, additional, Marconcini, R, additional, Mandalà, M, additional, Cimminiello, C, additional, Rinaldi, G, additional, Aglietta, M, additional, Calabrò, L, additional, and Maio, M, additional

Published
2013
Full Text
View/download PDF

47. High serum levels of soluble CD40-L in patients with undifferentiated nasopharyngeal carcinoma: pathogenic and clinical relevance.

Author

Caggiari, L, Guidoboni, M, Vaccher, E, Barzan, L, Franchin, G, Gloghini, A, Martorelli, D, Zancai, P, Bortolin, MT, Mazzucato, M, Serraino, D, Carbone, A, De Paoli, P, Dolcetti, R, Caggiari, L, Guidoboni, M, Vaccher, E, Barzan, L, Franchin, G, Gloghini, A, Martorelli, D, Zancai, P, Bortolin, MT, Mazzucato, M, Serraino, D, Carbone, A, De Paoli, P, and Dolcetti, R

Abstract

BACKGROUND: Engagement of CD40 promotes survival of undifferentiated nasopharyngeal carcinoma (UNPC) cells and similar effects are induced by the EBV oncoprotein LMP-1 that is expressed in a fraction of cases. Considering that CD40 may be activated also by the soluble isoform of CD40L (sCD40L), we investigated the serum levels of sCD40L in a series of 61 UNPC patients from Italy, a non-endemic area for this disease. RESULTS: At diagnosis, serum samples of UNPC patients contained significantly higher levels of sCD40L than age-matched healthy controls (p < 0.001). High levels of sCD40L (i.e., >18 ng/ml) were more frequently found in patients <40 years of age (p = 0.03) and with distant metastases at presentation (p = 0.03). Serum levels of sCD40L were inversely associated with the expression of the EBV oncoprotein LMP-1 (p = 0.03), which mimics a constitutively activated CD40. The amount of sCD40L decreased in a fraction of patients treated with local radiotherapy alone. Moreover, CD40L+ lymphoid cells admixed to neoplastic UNPC cells were detected in cases with high serum levels of sCD40L, suggesting that sCD40L is probably produced within the tumor mass. CONCLUSION: sCD40L may contribute to CD40 activation in UNPC cells, particularly of LMP-1-negative cases, further supporting the crucial role of CD40 signalling in the pathogenesis of UNPC. sCD40L levels may be useful to identify UNPC patients with occult distant metastases at presentation.

Published
2007

49. Dendritic cell (DC) vaccination with low dose temozolomide phase I/II trial in melanoma patients: Preliminary data on peripheral blood regulatory t-cells (Treg) and DC-TEM8 expression modulations.

Author

Petrini, M., primary, Ridolfi, L., additional, Fiammenghi, L., additional, Napolitano, M., additional, Granato, A. M., additional, Ancarani, V., additional, Pancisi, E., additional, Guidoboni, M., additional, Nicoletti, S., additional, Valmorri, L., additional, Riccobon, A., additional, Migliori, G., additional, Venanzi, F. M., additional, Ascierto, P. A., additional, and Ridolfi, R., additional

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results